The values for HER2 positivity in our article from 2005 were 79% for primary tumors and 62% for metastases when ≥2/3 of the tumor cells had to be HER2-stained and the staining should be as intense as for breast cancer sections.22 The internationally recommended DAKO procedure25 which we used this time gave 60/72 (83%) and 53/72 (74%) HER2-positive cases in the analyzed primary tumors and metastases, respectively. The gene discussed is ERBB2; the disease is breast carcinoma.